| Host: |
Rabbit |
| Applications: |
WB/IHC-P/ELISA |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
PBS with 0.05% Proclin300, 50% Glycerol, pH 7.3. |
| Purification: |
Affinity purification |
| Concentration: |
Lot specific |
| Dilution Range: |
WB:1:500-1:1000IHC-P:1:50-1:200ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
YTHDF1 |
| Gene ID: |
54915 |
| Uniprot ID: |
YTHD1_HUMAN |
| Immunogen Region: |
280-390 |
| Specificity: |
Recombinant fusion protein containing a sequence corresponding to amino acids 280-390 of human YTHDF1 (NP_060268.2). |
| Immunogen Sequence: |
VPKAPVPQQAPSPQAAPQPQ QVAQPLPAQPPALAQPQYQS PQQPPQTRWVAPRNRNAAFG QSGGAGSDSNSPGNVQPNSA PSVESHPVLEKLKAAHSYNP KEFEWNLKSGR |
| Function | Specifically recognizes and binds N6-methyladenosine (m6A)-containing mRNAs, and regulates their stability. M6A is a modification present at internal sites of mRNAs and some non-coding RNAs and plays a role in mRNA stability and processing. Acts as a regulator of mRNA stability by promoting degradation of m6A-containing mRNAs via interaction with the CCR4-NOT complex. The YTHDF paralogs (YTHDF1, YTHDF2 and YTHDF3) shares m6A-containing mRNAs targets and act redundantly to mediate mRNA degradation and cellular differentiation. Required to facilitate learning and memory formation in the hippocampus by binding to m6A-containing neuronal mRNAs. Acts as a regulator of axon guidance by binding to m6A-containing ROBO3 transcripts. Acts as a negative regulator of antigen cross-presentation in myeloid dendritic cells. In the context of tumorigenesis, negative regulation of antigen cross-presentation limits the anti-tumor response by reducing efficiency of tumor-antigen cross-presentation. Promotes formation of phase-separated membraneless compartments, such as P-bodies or stress granules, by undergoing liquid-liquid phase separation upon binding to mRNAs containing multiple m6A-modified residues: polymethylated mRNAs act as a multivalent scaffold for the binding of YTHDF proteins, juxtaposing their disordered regions and thereby leading to phase separation. The resulting mRNA-YTHDF complexes then partition into different endogenous phase-separated membraneless compartments, such as P-bodies, stress granules or neuronal RNA granules. |
| Protein Name | Yth Domain-Containing Family Protein 1Df1Dermatomyositis Associated With Cancer Putative Autoantigen 1Daca-1 |
| Cellular Localisation | CytoplasmP-BodyStress Granule |
| Alternative Antibody Names | Anti-Yth Domain-Containing Family Protein 1 antibodyAnti-Df1 antibodyAnti-Dermatomyositis Associated With Cancer Putative Autoantigen 1 antibodyAnti-Daca-1 antibodyAnti-YTHDF1 antibodyAnti-C20orf21 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
